Twitter-Delivered CME/CE on
Oncology from @onc_ce
Clinical trial data now exit the research facility and enter the practice landscape at unprecedented speed and volume, and the arrival of COVID-19 has not slowed this rapid flow of information. In fact, the pandemic has shifted the release of data to even more accessible digital formats. At this point, clinicians who manage cancer and who hope to stay current and apply new research to their daily practice cannot do so on their own; they benefit from an expert’s interpretation and distillation of data as they carry new information from conference to bedside. The need for distilled information presented in an applicable format has risen faster than ever.
The heterogeneity seen in various tissue tumor types reveals a need for ever-more individualized approaches that targets molecular subtype, genetic mutations, and immunological profile for each patient. Our accredited tweetorial feed, with each program authored by international experts, provides a forum for interaction, communication, and education for all healthcare providers with an interest in cancer.
Our Tweetorials
Your new source for free CE/CME via Twitter!
Each program provides 0.5hr – 1.0hr credit for physicians, pharmacists, and nurses.
MDS: The PCP Perspective and Role in Diagnostic Suspicion and Management
2) Our expert author is Vijaya Raj Bhatt, @VijayaRBhatt1 MBBS, MS, Section Leader, Malignant Hematology, @UNMCHemeOnc @UNMC_IM...
The Emerging Role of Anti-CTLA4 Therapeutics in NSCLC
2) This program, intended for #healthcare providers, includes updates from #ESMO22 @myESMOIt is supported by an independent educational grant from...
Utilizing Immunohistochemistry Testing, Biomarkers, and Targeted Therapeutics to Optimize Outcomes in Patients with NSCLC
2) The faculty for this outstanding program were @peters_solange (Chair) 🇨🇭, @HosseinBorghaei 🇺🇸, Natasha Leighl MD 🇨🇦, and @dplanchard 🇫🇷. A truly...
Patient-Reported Outcomes in Cancer Care
2) Our expert author is Thomas LeBlanc, MD @tomleblancMD, patient experience & cancer outcomes researcher @DukeCancer. Thanks for joining!...
A Review and Analysis of the Latest Data for Therapeutics from ASH 2022 in Relapsed/Refractory Multiple Myeloma—Part 2
1b) Now you can earn ANOTHER 0.5h credit with Joseph Mikhael MD @jmikhaelmd of @TGEN & #CMO of @IMFmyeloma, the 🥇& largest org dedicated to...
A Review and Analysis of the Latest Data for Therapeutics from ASH 2022 in Relapsed/Refractory Multiple Myeloma
2) Now we are covering @ASH_hematology 2022 #ASH22, which just occurred in December! Our expert guides are Joseph Mikhael MD @jmikhaelmd of...
Current Treatment Guidelines Concerning First-Line Therapy for ES-SCLC and Clinical Trial Review for New and Emerging Treatments
1b) Our expert author is Nicolas Girard @nicogirardcurie, #lungcancer & rare #thoracic #tumors specialist from Institut Curie, Paris...
The Role of CEACAM5-Targeted Therapeutics to Improve Outcomes in Patients with CEA-Positive NSCLC, with New Data from ESMO-IO 2022
1b) Our expert authors are @NarjustFlorezMD, Assoc. Director CCEP & Thoracic Oncology @DanaFarberNews and her mentee @ShrutiPatelMD, #MedOnc...
Strategies for Implementing Optimal First-Line Treatment of Patients with ES-SCLC
2) I am Dr. Sandip Patel @PatelOncology, Professor in Medical Oncology from @UCSDCancer. @nicogirardcurie (to follow) and I will be covering Optimal...
ESMOImmuno22 Update: Clinical Trial Review for Biomarker-Driven Targeted Therapeutics, Including CEACAM5 for Patients with NSCLC
2) I am Dr. Aakash Desai (@ADesaiMD) from @MayoHemOnc @MayoCancerCare @HemOncFellows @Oncoalert and now we are covering @myESMO #ESMOImmuno22...
@ONC_CE on Twitter
Your only source for ACCREDITED SoMe-delivered serialized professional oncology education. Physicians, nurses, pharmacists–come one, come all!
On Twitter at @onc_ce, we present a series of tweetorials, Twitter-delivered case studies, and Twitter Journal Clubs, each accredited for 0.5hr – 1.0hr CE/CME. Programs are presented by expert faculty in engaging and fully interactive format. Our unique program harnesses the reach, up-to-the-minute currency, and accessibility of social media to deliver a constant flow of accredited, interactive, expert-delivered educational programs to a multidisciplinary and interprofessional audience of engaged clinicians.